Equal Access to Therapeutics Act
Summary
Equal Access to Therapeutics Act This bill prohibits using race or ethnicity as a factor in decisions about an individual's access to COVID-19 treatments (e.g., monoclonal antibody therapies). Specifically, the Department of Health and Human Services (HHS) may not adopt any policy or guidance that allows race or ethnicity to be factored into such decisions. Furthermore, the Secretary of HHS shall be personally liable for the death of any individual who is denied access to COVID-19 treatments pursuant to a prohibited policy or guidance. The bill also prohibits hospitals or other health care providers that have policies restricting access to COVID-19 treatments based on race or ethnicity from receiving federal funds.
Bill status
in committee
1 of 4 stages cleared
Introduction
Feb 2022
Committee Review
Floor Vote
President
Introduced Feb 7, 2022
Last action Feb 8, 2022
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
3
Key actions
0
Committee
2
Feb 8, 2022
Committee
Referred to the Subcommittee on Health.
lower
Feb 7, 2022
Committee
Referred to the House Committee on Energy and Commerce.
lower
Feb 7, 2022
Introduced
Introduced in House
lower
1 primary · 16 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Rodney Davis
RRepublican
Co
Andrew R. Garbarino
RRepublican
Co
Beth Van Duyne
RRepublican
Co
Bob Gibbs
RRepublican
Co
Chris Jacobs
RRepublican
Co
Claudia Tenney
RRepublican
Co
David B. McKinley
RRepublican
Co
Doug Lamborn
RRepublican
Co
Glenn Grothman
RRepublican
Co
Jason Smith
RRepublican
Co
Jeff Fortenberry
RRepublican
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 6625
Scope: US
Hi! I can help you understand HR 6625. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline